Next Article in Journal
Inflammatory Alterations of the Extracellular Matrix in the Tumor Microenvironment
Next Article in Special Issue
Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans
Previous Article in Journal
Upregulation of Leukotriene Receptors in Gastric Cancer
Previous Article in Special Issue
Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(3), 3169-3188;

C-type Lectin Receptors for Tumor Eradication: Future Directions

Department of Molecular Cell Biology and Immunology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
Author to whom correspondence should be addressed.
Received: 3 June 2011 / Revised: 15 July 2011 / Accepted: 1 August 2011 / Published: 8 August 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
Full-Text   |   PDF [484 KB, uploaded 16 August 2011]   |  


Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4+ and CD8+ T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future. View Full-Text
Keywords: dendritic cells; glycans; antibodies; DC-targeting; immunotherapy dendritic cells; glycans; antibodies; DC-targeting; immunotherapy

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Streng-Ouwehand, I.; Unger, W.W.J.; Van Kooyk, Y. C-type Lectin Receptors for Tumor Eradication: Future Directions. Cancers 2011, 3, 3169-3188.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top